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1. Introduction 
The reciprocal osteoblast-osteoclast interactions are essential in the coordinated healthy 
bone formation and resorption. These communications in the bone microenvironment are 
highly complex events and need precise regulated molecular processes to ensure constant 
healthy bone remodeling. (Matsuo and Irie, 2008). Malignant bone tumors seem to be 
mainly linked to deregulation of this osteoblast-osteoclast cooperation processes. The major 
malignant bone tumor in pediatrics (5% of pediatric cancers) is high-grade osteosarcoma 
(OS). Usually, this bone cancer is diagnosed during adolescence and represent the second 
most common cancer after lymphoma in this period of age. A second peak observed in life is 
after 50 years. During adolescence, the kids are having their puberty development and the 
long bones are growing then particularly fast, with a rapid cell turnover in and around the 
growth plate (Mathew et al., 2011; Marina et al., 2004). Then, in a not surprising way, the 
most common locations of OS are the long bones (frequently, distal femur, proximal tibia 
and humerus) and especially in these metaphyseal regions around growth plates. 
Furthermore, no significant improvement in prognosis for patients with OS was observed 
since the advent of multiagent chemotherapy, increasing the long term outcome. Even this 
therapeutic progress, the overall survival of the patients is now at a plateau of 70% (Le 
Deley et al., 2007; Mirabello et al., 2009). After increasing the patient survival, new 
challenges regarding chemoresistances are now appearing  and are involved in the 
recurrence of the disease despite a successful local resection. 15 to 20% of diagnosed patients 
will have radiographically detectable pulmonary metastases whereas 80% will already 
presenting undetectable micrometastases (Bruland et al., 2009). The lack of prognostic 
marker at diagnosis is another key point in this cancer. The only prognostic marker is the 
Huvos histological grading on tumor resection after neo-adjuvant chemotherapy (Juergens 
et al., 1981). It is classifying patients into good responders to chemotherapy and poor 
responders but after 4-month-chemotherapy already done. All these epidemiologic and 
therapeutic characteristics initially led to develop molecular research to find new prognostic 
biomarkers and to define new therapeutic targets. In this context, the research focused on 
several genetic predisposition genes implicated in OS development even most OS tumors 
are sporadic cases without familial patterns. Rapidly thereafter, the OS molecular research 
was taking into account the worldwide well-known OS histological features, which are the 
presence of malignant osteoid matrix produced by the proliferating malignant osteoblastic 
cells. This definition underlie the fact that OS may be considered as a disease of osteoblast 
www.intechopen.com
 
Osteosarcoma 
 
140 
dedifferentiation (Haydon et al., 2007). As the normal osteoblasts derived from multipotent 
mesenchymal stem cells (MSCs), the several steps of this transition may be disrupted to 
obtain subsequently malignant osteoblasts. Based on that, multiple research teams focused, 
then, on osteoblast differentiation disruptions. They demonstrated that osteosarcomagenesis 
may result in a deregulation of normal osteogenesis signaling pathways, such as Wnt, BMP 
(Bone morphogenetic protein) or FGF (Fibroblast Growth Factor) (Entz-Werlé et al., 2003; 
Luo et al., 2007; Lau et al., 2007), and a dysexpression of several transcription factors (like 
Twist, Runx2, Osterix or ATF4) (Entz-werlé et al., 2005; Tang et al., 2008). These alterations 
result in the blockade of cells as undifferentiated precursors. The tumorigenesis seems to be 
also associated with disturbed bone metabolic activities, leading to the development of a 
penetrating tumor into the metaphyseal region of long bones and an increase in local bone 
destruction rates (Costa-Rodrigues et al., 2011; Avnet et al., 2008; Lamoureux et al., 2007). 
Osteogenesis and osteoclastogenesis signaling pathways additionally to bone 
microenvironment signals disruptions seem to contribute to OS development and its local or 
metastatic progression. 
The understanding of these deregulated molecular mechanisms in osteosarcoma has and 
will afford new prognostic markers and new therapeutic targets. In fact, multiple phase I 
and II, based on all these results, are still running and including relapsed osteosarcoma 
patients. The recent and increase use of zoledronic acid and targeted therapies in association 
with standard chemotherapy has to be considered as the emerging therapies of these last 
decade research in osteosarcomas (Lamoureux et  al., 2007;  Chou et al., 2008; Broadhead et 
al., 2011; PosthumaDeBoer et al., 2011). However, the major problem for targeted therapies 
in this bone cancer is the predominant observation of frequent deletions in karyotypic and 
arrayCGH (microarray based comparative genomic hybridization) approaches leading to 
develop therapeutic approaches by-passing the absence of protein over-expression.  
2. Research methodology  
In such malignant tumors, 3 main models for molecular and cellular studies are available: 
patient tumor collections, animal models and osteosarcoma cell lines (Kim & Helman, 2009).  
To optimize such high throughput molecular researches, the tumor collections have to be 
integrated into clinical trials to be able to collect in parallel the clinical data and to perform 
informative statistical correlations. These integrated translational researches have to 
investigate, first, homogenously treated patient cohorts in case of correlations with response 
to chemotherapy before any validation as independent marker(s) in several collections. In 
fact, the response to neo-adjuvant chemotherapy is depending on chemotherapeutic 
treatment itself and the percentage of response is usually modified by any chemotherapeutic 
changes in the protocols. Furthermore, this malignant bone tumor is having specific key 
problems turning around the nature of the tumor itself and its high frequency of extended 
spontaneous necrosis. This histological observation is impacting especially on RNA extract 
quality and consequently their analyses, explaining why numerous Lab focused on DNA 
extracts and paraffin-embedded samples for this tumor. The high complexity of 
chromosomal rearrangements (Sandberg et al., 2004) is also limiting the transcriptomic 
screening because of the difficulties in interpreting expression results. Nevertheless, 
genome-wide approaches to identify OS-associated genes were performed at DNA, RNA 
and proteomic levels during the last decade, as well as quantitative PCRs, mutation 
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researches or sequencing, for example (Kubista et al., 2011; Luk et al., 2011; Smida et al., 
2010; Lau, 2009). Wide epigenetic and polymorphism screening were also performed and 
allowed to detect complementary results (Sadikovic et al., 2008). 
However, to by-pass the difficulties in tumor collections, in vitro and in vivo models were 
developed. As models, they allowed also to confirm the mechanistic conclusions obtained 
from patients tumors. The in vitro models are based on the establishment of patient cell lines 
and/or the use of commercial cell lines (SaOS or U2OS, for example) (Janeway & Walkley, 
2011). Classical two-dimensional (2D) cultures can be done but it is lacking the mechanical 
and chemical features present in animal models and in the patient bone microenvironment. 
Therefore, three-dimensional assays were developed to create ideal conditions to study OS 
cell invasion and metastases (Xu et al., 2007). The 3D in vitro cell culture systems will allow 
live cell-based arrays, microfluidic cell culture systems and drug screening. The use of 
emerging microengineering approaches will provide repeatable 3D cell based assays and 
will allow large drug testing without the disadvantages and constraints of animal models 
(Tan et al., 2011; Xu & Burg, 2007).  
The third research model will be based on animal models (mainly mouse, rodent or dog 
model). The mouse models can be transgenic mice or genetically engineered mice (with the 
controlled induction of gene over-expression or under-expression), subcutaneous 
implantation into immunocompromised mice or orthotopic models. OS may also be induced 
frequently by mouse irradiation and/or the use of chemical carcinogens. The emerging 
rodent model in OS seem to be progressively used in the recent lab studies and have 
promising advantages. The dog seem to be also in OS a promising model because of 
multiple similarities with human cancer and it is offering the possibilities to study 
autochthonous tumors (Mueller et al., 2007). The in vivo model has to re-create human 
conditions to optimize the mechanistic understanding of osteosarcomagenesis, reason why 
several models of localized or metastatic OS were developed (Jones, 2011; Janeway & 
Walkley, 2011; Entz-Werlé et al., 2010;  Walkley et al., 2008; Dass et al., 2007; Ek et al., 2006; 
Dass et al., 2006; Luu et al., 2005). All these animal models are outstanding tools to perform 
in vivo target validation, drug optimization and pre-clinical studies. Furthermore, with the 
new technologies using bioluminescence, the drug testing and in situ tumor follow up is 
becoming easier (Sottnik et al., 2010 ; Rousseau et al., 2010).  
3. Genetic predisposing disorders to OS development 
By the past, the starting point in molecular research was frequently based on the correlation 
between congenital gene mutations and their associated risk of cancer development. For OS, 
multiple germline mutations are presenting a higher risk of OS. So, the Li and Fraumeni 
syndrome, an autosomal dominant disorder, is characterized by a germline mutation of 
TP53 and a high risk of OS development. The TP53 alterations (mutations, gene 
rearrangements or allelic loss) are frequently observed in sporadic OS (Smith-Sorensen et al., 
1993) and usually associated with chemoresistance (Asada et al., 1998). The second most 
frequent germline mutation associated with OS initiation is the hereditary retinoblastoma 
(Toguchida, et al., 1989), whereas the loss of heterozygosity of RB1 locus is also extremely 
frequent in sporadic OS. This RB1 loss is lacking in case of p16 loss expression (Nielsen et 
al., 1998) and has been demonstrated as a poor prognosis biomarker (Feugeas et al., 1996). 
The third group of cancer predisposition syndromes is linked to mutations of RECQ 
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helicases. Among them, Rothmund-Thomson syndrome (mutation of RECQL4), Bloom 
syndrome (mutation of BLM gene) and Werner syndrome (mutation of WRN gene) can be 
listed. All these syndromes are presenting similar clinical features and exhibit 
predispositions to develop OS (Wang, 2005). These mutations are known to increase 
sensitivity to DNA-damaging agents and maybe are predisposing to bone cell 
dedifferentiation and consequently to develop OS. Finally, the Paget disease of bone is also a 
heritable disorder characterized by the increased risk of OS development (approximately 1% 
of patients). This adult disease is defined as a rapid bone remodeling leading to abnormal 
bone production (McNairn et al., 2001). The pathogenesis of the Paget disease of bone was 
highlighting the role of FOS gene, as well as RANK or OPG, involved in bone formation. 
Most of these congenital disease are characterized by the alteration of genes involved in 
sporadic OS and most of them are part of osteoblast-osteoclast interactions, implicated in 
osteosarcomagenesis, as it will be developed below.  
4. The role of a defective osteogenesis in osteosarcoma development 
The MSCs are bone marrow stromal cells that can differentiate into osteogenic, 
chondrogenic, adipogenic, neurogenic or myogenic lineages (Deng et al., 2008). The 
osteogenic differentiation, a tightly regulated process, is needed for bone formation. At each 
successive stage of differentiation, the precursors are losing their proliferative ability until 
their terminal differentiation in mature osteoblast (Tang et al., 2008). This osteogenic 
differentiation is under the control of multiple markers including in particular connective 
tissue growth factor (CTGF), alkaline phosphatase (ALP), Osterix, Runx2, TWIST, 
osteopontin (OPN), osteocalcin (OCN) and collagen IaI. During the endochondral 
osteogenesis of long bones, the chondrogenic cascade is also needed for the bone formation 
and is regulated by multiple growth factors and transcription factors such as SOX9, BMP2, 
BMP7, and FGF2 (Deng et al., 2008). The cross-talk and feedback cycles between these two 
cascades are mainly based on the BMPs, PPAR┛, Runx2 and the canonical Wnt signaling 
pathway. Several cell cycle genes are also interacting directly or indirectly at several steps of 
osteoblastic lineage with osteogenic differentiation genes and signaling pathways. Looking 
closely to these normal features, OS cells are really comparable to undifferentiated 
osteogenic precursors with a high proliferative capacity, a resistance to apoptosis and a 
differential expression of osteogenic markers, such as CTGF, Runx2, ALP, Osterix, 
Osteopontin and Osteocalcin. In fact, the late osteogenic markers, Osteocalcin and 
Osteopontin, and the early markers of osteogenesis, like ALP, are less expressed than in 
normal osteoblasts, whereas growth factors are up-regulated or down-regulated almost as in 
normal osteogenic cells (Luu et al., 2007; Rochet et al., 2003). Usually, malignant osteoblastic 
cells fail to undergo terminal osteoblastic differentiation. The aggressiveness and the 
metastatic potential of OS cells seem to depend on this dedifferentiation. Furthermore, OS 
cells seem to originate from mesenchymal stem cell which could involve at the initiation 
step cell cycle gene deregulations like p16/CDKN2 (Mohseny et al., 2009; Tang et al., 2008) 
or p53 (Tatria et al., 2006), followed by the defect of growth factor stimulation or their over-
expression. Other pathways implicated in further osteoblastic differentiation will interfere 
later on. In the further paragraphs, the different biomarkers will be artificially classified 
depending on their potential and main roles in OS development. Therefore, cell cycle genes 
will be first described, followed by the major osteoblastic growth factors involved in OS 
dedifferentiation and in OS proliferation, as well as the Wnt signaling pathway. The main 
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transcription factors of osteoblastic differentiation will be discussed thereafter in order to 
understand from the very early steps to the last one how they are acting and could interfere 
into OS initiation step and/or metastatic spread. Most of the growth and transcription 
factors listed below are precisely modulated during skeletal development and will be over-
expressed or under-expressed, when needed in osteoblastic cells, in osteoclasts and/or for 
cell-matrix interactions. Most of the deregulations characterized in OS cells are also based on 
this modulated expression explaining why some of these molecular factors are at once under 
or over-expressed depending on the model of research and the status of OS cells.  
The chapters below and the figure 1 are explaining the involvement of the multiple normal 
osteogenic signaling patways and their deregulations in osteosarcoma cells. 
4.1 The cell cycle genes  
In OS, cell cycle genes like p53, Rb, p16, MDM2, CDK4 or FOS are implicated as in most of 
the other cancers. In this malignant bone tumor, numerous cytogenetic studies described a 
variety of genetic alterations like the inactivation of Rb and/p53 pathways. These two genes 
are usually very frequently altered (Entz-Werlé et al., 2003) but they are functioning as co-
activator of transcription factor like Runx2 (Thomas et al., 2004). MDM2 and p53 dys-
expressions are also cooperating to disrupt the osteogenic differentiation into a osteoblastic 
precursor (Lengner et al., 2006). Because of their high frequency alterations, they were 
suspected to be part of the initiation step of osteosarcomagenesis, as already demonstrated 
in publications showing the MSC implication in the origins of OS. All these characteristics 
were also confirmed in genetically engineered mice  where cell cycle genes are defective 
(Janeway & Walkley, 2011; Walkley et al., 2008).  
4.2 the osteoblastic growth factors and their receptors, which are favoring the OS cell 
dedifferentiation 
Fibroblast growth factors (FGFs) are growth factors favoring in tumor cells the increase of 
motility and the cell ability to microenvironment invasion.  Their main receptors, FGFR1, 
FGFR2 and FGFR3 were described as essential osteoblastic cell surface receptors, as the 
inherited mutation of these genes result in skeletal dysplasia (Kan et al., 2002; Bellus et al., 
2000; Bellus et al., 1996). During intramembranous ossification, FGFR4 seems to be also an 
important regulator of osteogenesis with involvement in preosteoblast proliferation, as well 
as in osteoblast functioning, explaining why it is more frequently amplified than the other 
FGFRs (Entz-Werlé et al., 2007a). In OS cell, alterations of the FGFs/FGFRs systems are less 
frequent than other genes (Entz-Werlé et al., 2007a; Mendoza et al., 2005), but they are 
playing a role in the activation of Runx2, which is stimulated by the activated Protein Kinase 
C  (Kim et al., 2006), and in the modulation of OS cell interactions with thebone matrix and 
vessels (Georgios et al., 2011).  
Connective Tissue growth Factor (CTGF), a member of the CCN family, is a modulator for 
osteoblast and chondrocyte differentiation and  is involved in vascular endothelial cell 
development during endochondral ossification (Luo et al., 2004). As in uncommitted 
preosteoblast progenitors, CTGF is up-regulated in most of the OS cells (Luo et al., 2008; 
Perbal et al., 2008), contributing to maintain the undifferentiated status and may also be 
implicated in angiogenic pathway deregulation (mainly, VEGF and HIF1┙) during OS 
formation (Nishida et al., 2009).  
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4.3 The osteoblastic growth factors and their receptors, which are also involved in OS 
cell proliferation 
Bone Morphogenetic Proteins (BMPs) belong to the TGF┚ family and are considered as 
pivotal growth factors of early MSC commitment to osteogenic lineage. The osteogenic 
BMPs include 2, 4, 6, 7 and 9 (Deng et al., 2008; Tang et al., 2008; Reddi, 1998). Even at early 
stages of osteogenic differentiation, these BMPs are inducing the expression of CTGF, ALP, 
inhibitor of DNA-binding (Id), transcription factors, like TWIST and Runx2 (Hayashi et al., 
2007). The up-regulation of these specific BMPs in OS is predominantly promoting the 
tumor growth and OS cell proliferation (Luo et al., 2008) throughout the stimulation of most 
of its target genes listed above. They are also favoring the interactions between OS cells and 
the bone matrix. 
Platelet-derived Growth factor (PDGF)/ Platelet-derived Growth factor receptor (PDGFR) 
signaling is preferentially playing a role in the regulation of normal osteoblastic cell 
proliferation and, consequently, in the deregulation of OS cell proliferation. It is also 
promoting malignant cell motility (Kumar et al., 2010) and it is implicated in osteoblast-
osteoclast interactions (Sanchez-Fernandez et al., 2008). When the PDGF/PDGFR signaling 
pathway is stimulated, the patients are presenting a worst prognosis (Hassan et al., 2011; 
Entz-Werlé et al., 2007b).  
4.4 From early to later transcriptional factors of osteoblastic differentiation 
Twist, or Twist-1, and its homolog dermo1, or Twist-2, are basic helix-loop-helix (bHLH) 
transcription factor involved as others in osteoblastogenesis. Twist1 expression negatively 
regulates osteoblast differentiation and maintains osteoblastic cells in a osteoprogenitor-like 
state. Accordingly, Twist1 silencing enhances the osteoblast differentiation program, by acting 
at very early step, and mediates MSC commitment and growth (Isenman et al., 2009). This 
transcription factor is interacting with Id-1 and Id-2, other HLH proteins, and it is cooperating 
with Msx2 and BMPs. Twist1 downregulation alters usually Runx2 expression, whereas it is 
having at once a double effect on FGFR2 (an up-regulation or a repression activity). However, 
the main role of twist1 downregulation is resulting into a reduced cell apoptosis (Miraoui & 
Marie, 2010).  These functional roles are explaining the role of Twist 1 in case of deleted and 
amplified gene in the OS, respectively favoring disruption of cell apoptosis and 
dedifferentiation of OS cells (Entz-Werlé et al., 2005 and 2007). It seem also to act at the 
initiation step of OS development as it was demonstrated in a double mutant mouse with 
Twist haploinsufficiency (Entz-Werlé et al., 2010). Dermo1 is also acting as a negative regulator 
of osteochondrogenesis, while promoting MSC growth and proliferation throughout the 
regulation of Id1 and Id-2 gene expression (Tran et al., 2010 ; Zhang et al., 2008). It is a direct 
transcription target of the canonical Wnt pathway and it is participating to the feedback loop 
of this pathway (Tran et al., 2010), but it was still yet not involved in OS development. 
Runx2 is a member of the DNA-binding transcription factor family that regulates the 
expression of multiple genes involved in cellular differentiation and cell-cycle progression. 
It is genetically essential for bone development and osteoblast maturation. It is interacting 
with numerous transcription activators and repressors such as Rb, PTH/PTHrP, MAPLK 
and histone deacetylases (Deng et al., 2008; Thomas et al., 2004). It is also a critical regulator 
in BMP-mediated osteogenic  differentiation and is having interactions during normal 
osteogenesis with the Wnt signaling pathway. It is physically interacting with the 
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hypophosphorylated form of Rb to promote terminal cell cycle exit and the differentiated 
osteoblastic phenotype (Thomas et al., 2004). It is acting at the pre-osteoblastic step after its 
activation by IHH (Indian Hedge Hog). In OS tumors, Runx2 is frequently over-expressed 
leading to stop osteoblast maturation and to promote metastatic spread (Thomas et al., 2004; 
Won et al., 2009), favoring the development of a highly aggressive disease and less 
differentiated OS cells (Martin et al., 2011). Controversially, other publications observed 
Runx2 low expression in OS cells (Entz-Werlé et al., 2010; Luo et al., 2008). These opposite 
results are not to be oddly considered and should provoke debate around the schedule of 
Runx2 activation or under-expression during osteosarcomatogeneis. In fact, a higher 
expression is needed in case of OS initiation and at metastatic spread but in the interval 
period, Runx2 could have a normal expression or could be under-expressed (Thomas et al., 
2004). Its counterparts Runx1 and Runx3 are also having potential but discussed roles in 
osteoblastic and chondrogenic differentiation, but up to date and to our knowledge no data 
are available on their potential implication in OS cells.  
Osterix is a zinc finger-containing transcription factor, which is, as Runx2, an important 
regulator of osteogenic differentiation (Deng et al., 2008), it is a downstream signal after 
Runx2 action in osteoblastic cell lineage differentiation and seem to be regulated by Runx3. 
Its normal expression in osteoblastic cells is linked to less osteolysis and suppress the cell 
migration. It seems to have low expression in OS cells allowing to promote tumor growth 
and metastases (Cao et al., 2005). 
All these growth and transcription factors are more or less cooperating or interacting with 
the canonical Wnt signaling pathway and the metabolic pathways linked to bone 
angiogenesis (Broadhead et al., 2011; Wan et al., 2010; Araldi & Schipani, 2010; Deng et al., 
2008; Haydon et al., 2007; Luo et al., 2004), which are described below. 
4.5 Wnt osteoblastic signaling pathways 
The Wnt signaling pathway is characterized by the binding of Wnt proteins to the cell-
surface receptors of the Frizzled family and its co-receptor LRP5/6, causing, then, the 
activation of Dishevelled (DSH) family proteins. These activated DSH proteins are inhibiting 
a complex of proteins, including axin, GSK3 and APC proteins. This complex normally 
promotes the proteolytic degradation of ┚catenin. In case of Axin/GSK3/APC complex 
inhibition, ┚catenin will be stabilized and, then, able to enter the nucleus for interactions 
with TCF/LEF family transcription factors and to promote specific gene expression (for 
example, fibronectin, c-Myc or cyclin D1). During bone formation, this pathway is 
predominantly linked to limb development and seems to act in the terminal 
differentiation of osteoblast, shunting also away cells from the chondrogenic 
differentiation (Monaghan et al., 2001). An increase of lytic lesions is linked with the 
inhibition of this canonical pathway. In OS, the Wnt/┚catenin signaling is frequently 
activated (Entz-Werlé et al., 2003 and 2007a; Haydon et al., 2002). This up-regulation is 
correlated with osteoprogenitor proliferation and OS metastases (Iwaya et al., 2003), 
resulting from ┚catenin massive nuclear translocation and/or deletion of APC. The loss of 
APC at DNA and protein levels was also associated to a worst outcome and less response 
to pre-operative chemotherapy (Guimaraes et al., 2010; Entz-Werlé et al., 2007a). This Wnt 
up-regulation can also induce chemoresistance throughout the repression of a bone matrix 
proteoglycan, syndecan 2 (Dieudonné et al., 2010).  
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4.6 The angiogenic and metabolic signaling pathways: 
The other central pathways are those involved in angiogenesis, which is essential in normal 
intramembranous and endochondral ossifications, but also for tumor growth and metastatic 
spread. A balance between pro-angiogenic and anti-angiogenic factors is required to 
regulate precisely angiogenesis. This balance is tipped towards the favor of neovasculature 
by tissue hypoxia. Usually, in tumor environment, hypoxic conditions are stimulating the 
deubiquitination of Von Hippel Landau  (VHL) protein, which is releasing hypoxia-
inducible factor-1 alpha (HIF-1┙). The stabilized form of HIF-1┙ is stimulating the secretion 
of VEGF, which is also up-regulating via FGF and TGF┙ signaling. The hypoxia is also 
regulating processes such as apoptosis and metabolic adaptation with, in particular, the 
release of glycolytic enzymes. (Araldi & Schipani, 2010; Wan et al., 2010; Ishida et al., 2009). 
HIF-1┙ upstream signals is involving mTor, RAS/MAPK cascade and PTEN. The 
angiogenesis is also the key in OS cell-bone matrix interactions, which are described below. 
Among all angiogenic markers, a focus will be done on those specifically involved in OS 
cells from the receptor ligands to the downstream transcription factors and their target 
genes. The different growth factors and their receptors are rather implicated in metastatic 
spread (Mizobuchi et al., 2008). In the angiogenesis studies, circulating growth factors can be 
estimated at plasma level and could help us to appreciate the implicated circulating factors. 
Cystein-X-Cystein (CXC) chemokines and their receptors (CXCR) are proteins, containing 2 
highly conserved cystein residues at N-terminus, and activating usually the chemotaxis of 
different cells. They can be also involved in various cellular processes such as skeletal 
rearrangements, cell migration and cell adhesion (Fernandez et al., 2002). In OS, the 
circulating CXC chemokines  (CXCL4, CXCL6 and CXCL12) seem to present higher 
concentrations (Li et al., 2011), correlated with a worst outcome in patients. They also 
stimulate the specific angiogenic and hypoxic signaling pathways, which are favoring the 
metastatic spread. Moreover, in case of circulating OS cells, the CXCR/CXC chemokine 
system seems to drive the homing of these cells in the metastatic locations. So, the 
circulating OS cells expressing CXCR4 were preferentially re-localized in lung because of 
CXCL12/SDF-1 (Stromal cell-Derived Factor-1) high secretions in lung (Perissinotto et al., 
2005). This metastatic homing may, then, be  supported by the tricky release of CXC 
chemokines, which is under the control of VEGF (Oda et al. 2006). 
Vascular Endothelial growth factor (VEGF)-A is one of the most important members of 
VEGF family. There are 5 other members VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and 
placenta growth factor (PIGF). VEGFs are binding their receptors and consequently 
initiating the tyrosine kinase activation and the downstream signals. The results of this 
process is the vessel formation. VEGF-A was mainly involved in the angiogenic processes of 
OS. In this context, high levels of VEGF was regularly observed in OS and especially in 
metastatic forms. The VEGF combined with the proteoglycans in the bone matrix was up-
regulate MMP secretion in OS and, therefore, increasing the vessel formation but also the OS 
cells–bone matrix interactions. It is also inducing the release via the malignant cells of anti-
apoptotic factors (bcl-2 and survivin) to ensure ongoing endothelial cell proliferation and 
neovascularization, but it will also promote the secretion of pro-angiogenic factors like FGF 
or angiopoietin 1. These signaling pathway are also under control of HIF1┙/mTor 
stimulation (Yang et al., 2011 ; Hassan et al., 2011; Broadhead et al., 2011; Haydon et al., 
2007; Oda et al., 2006).  
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Hepatocyte Growth factor (HGF) and its receptor (MET) regulate usually mitogenesis, 
motility and morphogenesis. In case of deregulation, it will contribute to cell transformation 
and tumor progression. HGF was also described recently as part of the angiogenic pathways 
(Hoot et al., 2010). A over-expression of MET, inconstantly associated with HGF high 
secretion, was usually observed in OS confirming its role in tumor progression, in 
angiogenesis stimulation and its correlation with a poor outcome (Hassan et al., 2010; Patane 
et al., 2006; Coltella et al., 2003). Surprising results were obtained showing deletion of MET 
gene associated with a poor outcome and a link with metastases (Entz-Werlé et al., 2007a). 
The sensivity enhancement of tumor cells in case of MET/FAS concomitant activation could 
explain partially this difference. In fact, the deletion of MET could then be considered much 
more in these OS as un marker of drug resistance, which was described in other cancers 
(Accordi et al., 2007). 
Insulin like Growth Factor (IGF) systems play a key role in cellular metabolism, 
differentiation, proliferation, transformation and apoptosis, during normal and malignant 
growth of cells. In normal bone formation, IGF-I and II are known to have effects on cell 
proliferation and to be inducer of collagen synthesis (Bikle &Wang, 2011; Wang et al., 2006). 
The recent findings demonstrated that the lack of IGF-I or its receptor in osteoblasts is 
enhancing the signaling between osteoblasts and osteoclasts through RANKL/RANK or 
PTH. Nevertheless, their roles were recently extended to the regulation of tumor 
angiogenesis and postnatal vasculogenesis (Orciari et al., 2009). In OS, IGF I and II are often  
 
Fig. 1. A schematic summary of the major osteogenic signaling pathways involved in 
osteosarcomas 
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over-expressed. Even they are part of the osteoblastic growth regulator, they are also 
involved in energy homeostasis of the bone and therefore may inhibit the cell apoptosis 
(Hassan et al., 2011). 
mTor/HIF-1┙ signaling and their downstream signals are playing key roles in cell 
proliferation and tumor hypoxia, as described above. In OS, mTor was described as an 
activated protein and seem to promote concomitantly with other signals the tumor 
progression, whereas expression of HIF-1 was mainly associated with a metastatic disease 
(Zhou et al., 2010; Knowles et al., 2010; Mizobuchi et al., 2010). The downstream signals like 
VEGF were already described as part of OS oncogenesis. Finally, few publications involved 
in OS the glycolytic enzymes like pyruvate kinase, for example. However, these enzymes 
seem to have proliferation impact (Spoden et al., 2008).   
5. Deregulation of bone destruction mechanisms and cells (osteoclasts) is 
part of osteosarcoma progression  
Osteoclasts originate from macrophage lineage and this differentiation results from a series 
of molecular events associating osteoclastic signals and extracellular matrix compounds. 
Some of these factors are required for osteoclast proliferation and differentiation, like 
Macrophage-Colony Stimulating factor (M-CSF), while factors like receptor activator of 
nuclear k┚ ligand (RANKL) are more implicated in the commitment of macrophage 
precursors into osteoclasts and also in their survival. The RANKL/RANK activities are 
under the control of osteoprotegerin (OPG), which is blocking the ligand-receptor binding 
and subsequently the osteoclastogenesis and bone resorption (Baud'huin et al., 2011; 
Lamoureux et al., 2007). OPG is a potent apoptosis inhibitor of tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) on tumor cells. The loss of osteoclasts in the primary 
tumors enhances the OS metastases (Endo-Munoz et al., 2010a). The decrease of osteoclasts 
is consistent with a decreased antigen-presenting activity, an enhanced chemoresistance and 
an impaired osteoclastogenesis (Endo-Munoz et al., 2010b). Osteoclasts are also part of the 
vicious cycle between bone resorption and tumor cell proliferation during tumor 
development. In OS, the tumor secretion of bone-modulating compounds is stimulating 
osteoclastic bone resorption, impacting on the release of growth factors from extracellular 
bone matrix. The triad RANK/RANKL/OPG seem to have play a pivotal role in this vicious 
cycle (Lamoureux  et al., 2010). The osteoclast activity is also linked to TRACP 5A and 
MMP9 serum levels (Avnet et al., 2008).   
The bone metabolism implicate other regulators of bone turnover like parathyroid hormone 
(PTH) and  parathyroid hormone related protein (PTHrP), which have been implicated in 
OS progression and especially in metastatic OS spread. PTHrP could confer also 
chemoresistance by blocking signaling via p53, the death receptor and the mitochondrial 
pathways of apoptosis (Gagiannis et al., 2009). 
Upstream, the TGF┚, released from the degraded bone matrix, is acting on OS cells, 
stimulating the release of PTHrP, IL6 and IL11. These cytokines then stimulate osteoclasts, 
facilitating further invasion and release of pro-resorptive cytokines. After TGF┚ stimulation, 
PTHrP and IL11 also act on osteoblasts, stimulating increased expression of RANKL 
(receptor activator of nuclear factor xB ligand) and M-CSF (Endo-Munoz et al., 20010b).  
The normal bone microenvironment and osteosarcoma matrix during tumor development 
are providing optimal conditions for tumor cell proliferation and will facilitate blood vessel 
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formation. Various protein fibrils (fibronectin, collagens, proteoglycans, integrins and 
laminins) and growth factors stored in matrix are contributing to tumor cell adhesion and 
spread. This microenvironment is usually convenient to allow detachment of OS cells from 
the tumor, adhesion to the extracellular matrix , local migration and invasion through 
stromal tissue until vascular extravasation. Extracellular matrix components such as 
glycoaminoglycans (GAGs) are also participating to the bone metabolism. In OS, GAGs 
over-expression is inhibiting OPG action, is acting as regulator of OPG availability and is 
having anti-tumor activity in bone microenvironment (Lamoureux et al., 2010). Another 
component of the matrix, named Syndecan 2 (a cell surface heparin sulfate proteoglycan ), 
can induce apoptosis and sensitize OS cells to the cytotoxic effect of chemotherapies (Orosco 
et al., 2007; Modrowski et al., 2005). The integrins are also taking part of the bone matrix 
role in OS progression and seem to participate to the mTor/HIF1┙ signaling (Kim & 
Helman, 2009).    
Finally, the bone metabolism is regulating by the interactions between osteoclasts and 
osteoblasts, which are cell-cell contacts but are also initiating paracrine mechanisms. In fact, 
osteoblasts synthesize a variety of molecules important in the recruitment and survival of 
osteoclast precursors and these proteins will regulate the later steps of osteoclastogenesis 
(Costa-Rodrigues et al., 2010). As with normal osteoblasts, osteoclasts will be stimulated by 
the OS cells. In fact, the malignant cells  are usually presenting a high osteoclastogenic-
triggering capacity, which is contributing to the normal bone destruction by the tumor cells 
and explaining partially the "vicious cycle" described above and below in the figure 2.  
 
Fig. 2. A schematic summary of the bone vicious cycle involved in osteosarcoma 
development  
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6. Conclusion and future prognostic and therapeutic directions 
The increase knowledge in this complex network of markers and signaling pathways 
involved in OS cells is now allowing to pool and extrapolate these data in a preliminary 
multistep osteosarcomagenesis (Figure 3). 
 
Fig. 3. An extrapolate multistep osteosarcomagenesis 
Several of these biomarkers could be used as relevant prognostic factors but they have to be 
confirmed in larger cohorts of patients and as independent markers, like the histological 
Huvos  grading. Among all these striking results, targeted therapies could emerge. The 
osteoblastic growth factors could be downregulated in case of overexpression with, for 
example, large spectrum inhibitors of tyrosine kinase receptors. Various PPAR┛ agonists 
may be usable to prevent proliferation and to induce terminal differentiation of malignant 
cells, as well as multiple anti-angiogenic approaches (antagonists of CXCR4 or VEGFR, 
metronomic chemotherapy, inhibition of hypoxia signaling, for example). New drugs 
targeting Wnt signaling pathway are also upcoming and could be usable in the next future 
(Chou et al., 2008; Houghton et al., 2007).  
Finally, the bone destruction pathways are now considered as the larger field of innovative 
targeted therapies (Lamoureux et al., 2007;). The increased use of zoledronic acid in phase I 
and II but also in phase III is the proof of concept.  
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